A Phase 3 interventional study of Typhoid Vi Polysaccharide Vaccine and Yellow Fever Vaccine in Meningococcal Disease, Meningococcal Meningitis and Typhoid, sponsored by Novartis. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-03-11.
Sponsored by Novartis · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Meningitis, Meningococcal by Novartis — none open to participants now, none under way, none of them phase 3. Meningitis, Meningococcal · Novartis.
Among the 32 studies in Meningitis, Meningococcal by Novartis, this one is the 18th largest by enrollment of the 30 interventional ones that give a count, is one of 9 that started in 2011, is one of 19 in phase 3, and was the 28th registered.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
Browse Meningitis, Meningococcal studies →None of the 32 studies in Meningitis, Meningococcal by Novartis is open now. The open studies under Meningitis, Meningococcal, anywhere →
Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 10 · Phase 3 21 · Phase 4 1
First in 2005; this study’s year is marked. 9 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 552 is close to the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Median enrollment 707 across the 30 interventional studies, 27,895 across the 2 observational. Of the 32 that completed or were terminated, 28 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 32 studies in Meningitis, Meningococcal by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study compares the safety and immunogenicity profile of several travel vaccines given alone or concomitantly with MenACWY-CRM to healthy adults.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
This study's enrollment of 552 is close to the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Browse Meningitis, Meningococcal studies →Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
Compared within Meningitis, Meningococcal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Meningococcal Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female and male subjects who must be healthy and must be:
Exclusion Criteria:
Individuals not eligible to be enrolled in the study are those:
who have received live licensed vaccines within 30 days and inactive vaccine within 15 days prior to enrollment or for whom receipt of a licensed vaccine is anticipated during the study period.
(Exception: Influenza vaccine may be administered up to 15 days prior to each study immunization and no less than 15 days after each study immunization);
who have any serious acute, chronic or progressive disease such as:
who have a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from (for example):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide and yellow fever vaccine.
Biological: Typhoid Vi Polysaccharide Vaccine · Biological: Yellow Fever Vaccine
Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide, yellow fever and meningococcal ACWY conjugate vaccine.
Biological: Typhoid Vi Polysaccharide Vaccine · Biological: Yellow Fever Vaccine · Biological: MenACWY-CRM Vaccine
Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies vaccine.
Biological: Japanese Encephalitis Vaccine · Biological: Rabies Vaccine
Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies and one dose of meningococcal ACWY conjugate vaccine.
Biological: Japanese Encephalitis Vaccine · Biological: Rabies Vaccine · Biological: MenACWY-CRM Vaccine
Subjects ≥18 years to ≤60 years of age who received three doses of Rabies vaccine.
Biological: Rabies Vaccine
Subjects ≥18 years to ≤60 years of age who received one dose of meningococcal ACWY conjugate vaccine.
Biological: MenACWY-CRM Vaccine
One dose of typhoid Vi polysaccharide vaccine.
One dose of yellow fever vaccine.
Two doses of Japanese Encephalitis Vaccine.
Three doses of Rabies vaccine.
One dose of MenACWY-CRM vaccine.
Geometric Mean Anti-typhoid Vi Antibody Concentrations
Assessment was made to demonstrate the non-inferiority of the geometric mean anti-typhoid Vi antibody concentrations, 28 days after the vaccination of typhoid Vi polysaccharide (TF) and yellow fever (YF) vaccines given concomitantly with MenACWY-CRM197 to typhoid Vi polysaccharide and yellow fever vaccines given alone in healthy adults aged ≥18 years to ≤60 years.
Time frame: Baseline and 1 month postvaccination (day 29).
Geometric Mean Anti-Yellow Fever Antibody Titer
Assessment was made to demonstrate the non-inferiority of the geometric mean anti-yellow fever antibody titers, 28 days after the vaccination of typhoid Vi polysaccharide (TF) and yellow fever (YF) vaccines given concomitantly with MenACWY-CRM197 to typhoid Vi polysaccharide and yellow fever vaccines given alone in healthy adults aged ≥18 years to ≤60 years.
Time frame: Baseline and 1 month postvaccination (day 29).
Geometric Mean Anti-Japanese Encephalitis Neutralizing Antibody Titers
Assessment was made to demonstrate the non-inferiority of the geometric mean anti-Japanese encephalitis neutralizing antibody titers, 28 days after the vaccination of the second dose of Japanese Encephalitis vaccine and third dose of the rabies virus vaccine given concomitantly with MenACWY-CRM197 or alone in healthy adults aged ≥18 years to ≤60 years.
Time frame: Baseline and 1 month post last vaccination (day 57).
Geometric Mean Anti-Rabies Virus Neutralizing Antibody Concentration
Assessment was made to demonstrate the non-inferiority of the geometric mean anti-rabies virus neutralizing antibody concentrations, 28 days after the vaccination of the second dose of Japanese encephalitis vaccine and third dose of rabies virus vaccine given concomitantly with MenACWY-CRM197 or alone in healthy adults aged ≥18 years to ≤60 years.
Time frame: Baseline and 1 month post last vaccination (day 57).
Percentages Of Subjects With Anti-YF Neutralizing Antibody Titers ≥ 1/10, 28 Days After The Vaccination Of Typhoid Vi Polysaccharide And Yellow Fever, Concomitantly With MenACWY-CRM197 Or Given Alone
Immunogenicity was assessed as the percentages of subjects who achieved seroprotection as measured by neutralization test for anti-YF neutralizing antibody titers after the vaccination of typhoid Vi polysaccharide and yellow fever, given alone or concomitantly with MenACWY-CRM197 on day 29. Seroprotection is defined as percentages of subjects who achieved anti-YF neutralizing antibody titers ≥ 1/10 on day 29.
Time frame: Baseline and 1 month postvaccination (day 29).
Percentages Of Subjects With Anti-JE Neutralizing Antibody Titers ≥ 1/10, 28 Days After The Vaccination Of The Last Doses Of Japanese Encephalitis And Rabies, Given Concomitantly With MenACWY-CRM197 Or Alone
Immunogenicity was measured as the percentages of subjects who achieved seroprotection as measured by neutralization test for anti-Japanese encephalitis neutralizing antibody titers, 28 days after administration of the second dose of Japanese encephalitis virus vaccine and 28 days after the vaccination of third dose of rabies virus vaccine, given alone or concomitantly with MenACWY-CRM197. Seroprotection is defined as percentages of subjects who achieved anti-JE neutralizing titers ≥ 1/10 on Day 57.
Time frame: Baseline and 1 month post last vaccination (day 57).
Percentages Of Subjects With Anti-Rabies Virus Antibody Concentrations ≥ 0.5 IU/mL 28 Days After the Vaccination Of The Last Doses Of Japanese Encephalitis And Rabies Virus, Given Concomitantly With MenACWY-CRM197 Or Alone
Immunogenicity was assessed as the percentages of subjects who achieved seroprotection as measured by neutralization test for anti-rabies neutralizing antibody titers, 28 days after administration of the second dose of Japanese encephalitis virus vaccine and 28 days after the vaccination of third dose of rabies virus vaccine, given alone or concomitantly with MenACWY-CRM197. Seroprotection is defined as a subject with a baseline hSBA titer \< 1:4, seroresponse was defined as a post-vaccination hSBA titer ≥ 1:8; for a subject with a baseline hSBA titer ≥ 1:4, seroresponse was defined as a post-vaccination hSBA titer of at least 4 times the baseline.
Time frame: Baseline and 1 month post last vaccination (day 57).
Geometric Mean hSBA Titers For Meningococcal Serogroups A,C,W,Y 28 Days After The Vaccination Of MenACWY-CRM197 Given Concomitantly With Typhoid Vi Polysaccharide And Yellow Fever Vaccines Alone
Immunogenicity was assessed by Serum Bactericidal Assay using human complement (hSBA) geometric mean titers (GMTs) for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with typhoid Vi polysaccharide and yellow fever vaccines or alone.
Time frame: Baseline and 1 month postvaccination (day 29).
Seroresponse Rate For Meningococcal Serogroups A,C,W,Y 28 Days After Vaccination of MenACWY-CRM197 Given Concomitantly With Typhoid Vi Polysaccharide and Yellow Fever Vaccines or Alone
Immunogenicity was assessed by seroresponse rates as measured by human serum bactericidal activity (hSBA) titers for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with typhoid Vi polysaccharide and yellow fever vaccines or alone. Seroresponse is defined as a postvaccination hSBA titer ≥1:8; for a subject with a baseline hSBA titer ≥1:4, seroresponse is defined as a postvaccination hSBA titer of at least four times the baseline.
Time frame: 1 month postvaccination (day 29)
Geometric Mean hSBA Titers for Meningococcal Serogroups A,C,W,Y 28 Days After the Vaccination of MenACWY-CRM197 Given Concomitantly With Japanese Encephalitis and Rabies Virus Vaccines or Alone
Immunogenicity was measured by human serum bactericidal activity (hSBA) geometric mean titers (GMTs) for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with Japanese encephalitis and rabies virus vaccines or alone.
Time frame: Baseline and 1 month post last vaccination (day 29 or day 57).
Seroresponse Rate for Meningococcal Serogroups A,C,W,Y 28 Days After Vaccination of MenACWY-CRM197 Given Concomitantly With Japanese Encephalitis and Rabies Virus Vaccines or Alone
Immunogenicity was assessed by seroresponse rates as measured by human serum bactericidal activity (hSBA) titers for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with Japanese encephalitis and rabies virus vaccines or alone. Seroresponse is defined as a subject with a baseline hSBA titer \< 1:4, seroresponse was defined as a post-vaccination hSBA titer ≥ 1:8; for a subject with a baseline hSBA titer ≥ 1:4, seroresponse was defined as a postvaccination hSBA titer of at least 4 times the baseline.
Time frame: 1 month post last vaccination (day 29 or day 57)
Geometric Mean Rabies Virus Neutralizing Antibody Concentration 28 Days After the Last Vaccination Of Rabies Virus Vaccine Concomitantly Either With Japanese Encephalitis or With Japanese Encephalitis And MenACWY-CRM197
The immunogenicity was assessed in rabies virus vaccine as measured by geometric mean rabies virus neutralizing antibody concentration, 28 days after vaccination of the third dose, when administered alone or concomitantly either with Japanese encephalitis vaccine or with Japanese Encephalitis and MenACWY-CRM197 vaccines.
Time frame: Baseline and 1 month post last vaccination (day 57).
Percentages of Subjects With Anti-rabies Virus Concentrations ≥ 0.5 IU/mL, 28 Days After the Last Vaccination of Rabies Virus Vaccine Concomitantly Either With Japanese Encephalitis or With Japanese Encephalitis and MenACWY-CRM197
Immunogenicity was measured as the percentages of subjects who achieved seroprotection of anti-rabies virus antibody concentrations 28 days after vaccination of the third dose of rabies virus vaccine, when administered alone or concomitantly either with Japanese encephalitis or with Japanese encephalitis and MenACWY-CRM197 vaccines. Seroprotection is defined as percentages of subjects who achieved anti-rabies virus antibody concentrations ≥ 0.5 IU/mL on day 57.
Time frame: Baseline and 1 month post last vaccination (day 57).
Number of Subjects With Adverse Events of Special Interest After Any Vaccination of Japanese Encephalitis and Rabies Virus Vaccines Given Concomitantly With MenACWY-CRM197 or Alone
In addition to the AEs and SAEs. Additional AESI were collected from day 1 to day 57 postvaccination in subjects after the vaccination of Japanese encephalitis and rabies virus vaccines given concomitantly with MenACWY-CRM197 or alone.
Time frame: day 1 to day 57 post last vaccination
Subjects were enrolled at 5 sites (Berhard Nocht Institut, Germany, Berliner Centrum fuer Reise, Germany, Universitat Rostock, Germany, University of Munich, Germany, Vacc and Travel Med. Center, Czech Republic)
| Milestone | TF+YF | TF+YF+MenACWY-CRM197 | JE+Rabies | JE+Rabies+MenACWY-CRM197 | Rabies | MenACWY-CRM197 (Combined) |
|---|---|---|---|---|---|---|
| Started | 101 | 100 | 99 | 101 | 51 | 100 |
| Completed | 100 | 100 | 98 | 99 | 51 | 99 |
| Not completed | 1 | 0 | 1 | 2 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 1 | 0 | 0 |
Assessment was made to demonstrate the non-inferiority of the geometric mean anti-typhoid Vi antibody concentrations, 28 days after the vaccination of typhoid Vi polysaccharide (TF) and yellow fever (YF) vaccines given concomitantly with MenACWY-CRM197 to typhoid Vi polysaccharide and yellow fever vaccines given alone in healthy adults aged ≥18 years to ≤60 years.
| El.U/mL | TF+YF | TF+YF+MenACWY-CRM197 |
|---|---|---|
| Day 1 (Typhoid Fever) | 6.37 (5.3 to 7.65) | 5.6 (4.66 to 6.73) |
| Day 29 (Typhoid Fever) | 134 (104 to 174) | 153 (118 to 197) |
Assessment was made to demonstrate the non-inferiority of the geometric mean anti-yellow fever antibody titers, 28 days after the vaccination of typhoid Vi polysaccharide (TF) and yellow fever (YF) vaccines given concomitantly with MenACWY-CRM197 to typhoid Vi polysaccharide and yellow fever vaccines given alone in healthy adults aged ≥18 years to ≤60 years.
| Titers | TF+YF | TF+YF+MenACWY-CRM197 |
|---|---|---|
| Day 1 (Yellow Fever) | 9.05 (6.82 to 12) | 12 (8.68 to 15) |
| Day 29 (Yellow Fever) | 5244 (3929 to 7000) | 5022 (3754 to 6717) |
Assessment was made to demonstrate the non-inferiority of the geometric mean anti-Japanese encephalitis neutralizing antibody titers, 28 days after the vaccination of the second dose of Japanese Encephalitis vaccine and third dose of the rabies virus vaccine given concomitantly with MenACWY-CRM197 or alone in healthy adults aged ≥18 years to ≤60 years.
| Titers | JE+Rabies | JE+Rab+MenACWY-CRM197 |
|---|---|---|
| Day 1 (Japanese Encephalitis) | 5.61 (5.11 to 6.15) | 5.58 (5.09 to 6.12) |
| Day 57 (Japanese Encephalitis) | 183 (151 to 221) | 165 (136 to 199) |
Assessment was made to demonstrate the non-inferiority of the geometric mean anti-rabies virus neutralizing antibody concentrations, 28 days after the vaccination of the second dose of Japanese encephalitis vaccine and third dose of rabies virus vaccine given concomitantly with MenACWY-CRM197 or alone in healthy adults aged ≥18 years to ≤60 years.
| IU/mL | JE+Rabies | JE+Rab+MenACWY-CRM197 |
|---|---|---|
| Day 1 (Rabies) | 0.056 (0.05 to 0.062) | 0.049 (0.044 to 0.054) |
| Day 57 (Rabies) | 12 (9.68 to 14) | 11 (8.84 to 13) |
Immunogenicity was assessed as the percentages of subjects who achieved seroprotection as measured by neutralization test for anti-YF neutralizing antibody titers after the vaccination of typhoid Vi polysaccharide and yellow fever, given alone or concomitantly with MenACWY-CRM197 on day 29. Seroprotection is defined as percentages of subjects who achieved anti-YF neutralizing antibody titers ≥ 1/10 on day 29.
| Percentages of subjects | TF+YF | TF+YF+MenACWY-CRM197 |
|---|---|---|
| Day 1 (Yellow Fever) | 34 (25 to 44) | 36 (27 to 46) |
| Day 29 (Yellow Fever) | 100 (96 to 100) | 97 (91 to 99) |
Immunogenicity was measured as the percentages of subjects who achieved seroprotection as measured by neutralization test for anti-Japanese encephalitis neutralizing antibody titers, 28 days after administration of the second dose of Japanese encephalitis virus vaccine and 28 days after the vaccination of third dose of rabies virus vaccine, given alone or concomitantly with MenACWY-CRM197. Seroprotection is defined as percentages of subjects who achieved anti-JE neutralizing titers ≥ 1/10 on Day 57.
| Percentages of subects | JE+Rabies | JE+Rabies+MenACWY-CRM197 |
|---|---|---|
| Day 1 (Japanese Encephalitis) | 3 (1 to 9) | 4 (1 to 10) |
| Day 57 (Japanese Encephalitis) | 99 (94 to 100) | 98 (93 to 100) |
Immunogenicity was assessed as the percentages of subjects who achieved seroprotection as measured by neutralization test for anti-rabies neutralizing antibody titers, 28 days after administration of the second dose of Japanese encephalitis virus vaccine and 28 days after the vaccination of third dose of rabies virus vaccine, given alone or concomitantly with MenACWY-CRM197. Seroprotection is defined as a subject with a baseline hSBA titer \< 1:4, seroresponse was defined as a post-vaccination hSBA titer ≥ 1:8; for a subject with a baseline hSBA titer ≥ 1:4, seroresponse was defined as a post-vaccination hSBA titer of at least 4 times the baseline.
| Percentages of subjects | JE+Rabies | JE+Rabies+MenACWY-CRM197 |
|---|---|---|
| Day 1 (Rabies) | 3 (1 to 9) | 1 (0.026 to 5) |
| Day 57 (Rabies) | 100 (96 to 100) | 100 (96 to 100) |
Immunogenicity was assessed by Serum Bactericidal Assay using human complement (hSBA) geometric mean titers (GMTs) for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with typhoid Vi polysaccharide and yellow fever vaccines or alone.
| titers | MenACWY-CRM197 (Combined) | TF+YF+MenACWY-CRM197 |
|---|---|---|
| Serogroup A (Day 1) | 2.94 (2.43 to 3.56) | 2.78 (2.3 to 3.36) |
| Serogroup A (Day 29) | 65 (44 to 95) | 62 (42 to 90) |
| Serogroup C (Day 1) | 7.94 (5.94 to 11) | 7.03 (5.27 to 9.38) |
| Serogroup C (Day 29) | 49 (35 to 70) | 54 (38 to 76) |
| Serogroup W (Day 1) | 50 (35 to 71) | 32 (22 to 45) |
| Serogroup W (Day 29) | 129 (94 to 177) | 211 (154 to 290) |
| Serogroup Y (Day 1) | 7.61 (5.71 to 10) | 7.76 (5.83 to 10) |
| Serogroup Y (Day 29) | 89 (62 to 129) | 78 (54 to 113) |
Immunogenicity was assessed by seroresponse rates as measured by human serum bactericidal activity (hSBA) titers for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with typhoid Vi polysaccharide and yellow fever vaccines or alone. Seroresponse is defined as a postvaccination hSBA titer ≥1:8; for a subject with a baseline hSBA titer ≥1:4, seroresponse is defined as a postvaccination hSBA titer of at least four times the baseline.
| Percentages of subjects | TF + YF + MenACWY-CRM197 | MenACWY-CRM197 (Combined) |
|---|---|---|
| Serogroup A (Overall Seroresponse) | 72 (62 to 81) | 71 (61 to 79) |
| Serogroup C (Overall Seroresponse) | 48 (38 to 58) | 47 (37 to 58) |
| Serogroup W (Overall Seroresponse) | 51 (40 to 61) | 30 (21 to 40) |
| Serogroup Y (Overall Seroresponse) | 63 (53 to 72) | 66 (55 to 75) |
Immunogenicity was measured by human serum bactericidal activity (hSBA) geometric mean titers (GMTs) for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with Japanese encephalitis and rabies virus vaccines or alone.
| titers | JE + Rab + MenACWY-CRM197 | MenACWY-CRM197 (Combined) |
|---|---|---|
| Serogroup A (Day 1) | 3.21 (2.65 to 3.88) | 2.94 (2.43 to 3.56) |
| Serogroup A (Day 29 or Day 57) | 32 (22 to 47) | 65 (44 to 95) |
| Serogroup C (Day 1) | 8.81 (6.59 to 12) | 7.94 (5.94 to 11) |
| Serogroup C (Day 29 or Day 57) | 44 (31 to 62) | 49 (35 to 70) |
| Serogroup W (Day 1) | 54 (38 to 77) | 50 (35 to 71) |
| Serogroup W (Day 29 or Day 57) | 119 (87 to 164) | 129 (94 to 177) |
| Serogroup Y (Day 1) | 8.11 (6.08 to 11) | 7.61 (5.71 to 10) |
| Serogroup Y (Day 29 or Day 57) | 55 (38 to 80) | 89 (62 to 129) |
Immunogenicity was assessed by seroresponse rates as measured by human serum bactericidal activity (hSBA) titers for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with Japanese encephalitis and rabies virus vaccines or alone. Seroresponse is defined as a subject with a baseline hSBA titer \< 1:4, seroresponse was defined as a post-vaccination hSBA titer ≥ 1:8; for a subject with a baseline hSBA titer ≥ 1:4, seroresponse was defined as a postvaccination hSBA titer of at least 4 times the baseline.
| Percentages of subjects | JE + Rab + MenACWY-CRM197 | MenACWY-CRM197 (Combined) |
|---|---|---|
| Serogroup A (Overall Seroresponse) | 60 (49 to 69) | 71 (61 to 79) |
| Serogroup C (Overall Seroresponse) | 43 (33 to 54) | 47 (37 to 58) |
| Serogroup W (Overall Seroresponse) | 32 (23 to 42) | 30 (21 to 40) |
| Serogroup Y (Overall Seroresponse) | 56 (45 to 66) | 66 (55 to 75) |
The immunogenicity was assessed in rabies virus vaccine as measured by geometric mean rabies virus neutralizing antibody concentration, 28 days after vaccination of the third dose, when administered alone or concomitantly either with Japanese encephalitis vaccine or with Japanese Encephalitis and MenACWY-CRM197 vaccines.
| IU/mL | JE + Rabies + MenACWY-CRM197 | JE + Rabies | Rabies |
|---|---|---|---|
| Day 1 (Rabies) | 0.051 (0.044 to 0.059) | 0.057 (0.049 to 0.065) | 0.068 (0.056 to 0.082) |
| Day 57 (Rabies) | 11 (8.84 to 13) | 11 (9.49 to 14) | 8.97 (6.98 to 12) |
Immunogenicity was measured as the percentages of subjects who achieved seroprotection of anti-rabies virus antibody concentrations 28 days after vaccination of the third dose of rabies virus vaccine, when administered alone or concomitantly either with Japanese encephalitis or with Japanese encephalitis and MenACWY-CRM197 vaccines. Seroprotection is defined as percentages of subjects who achieved anti-rabies virus antibody concentrations ≥ 0.5 IU/mL on day 57.
| Percentages of subjects | JE + Rabies + MenACWY-CRM197 | JE + Rabies | Rabies |
|---|---|---|---|
| Day 1 (Rabies) | 1 (0.026 to 5) | 3 (1 to 9) | 8 (2 to 19) |
| Day 57 (Rabies) | 100 (96 to 100) | 100 (96 to 100) | 100 (93 to 100) |
In addition to the AEs and SAEs. Additional AESI were collected from day 1 to day 57 postvaccination in subjects after the vaccination of Japanese encephalitis and rabies virus vaccines given concomitantly with MenACWY-CRM197 or alone.
| subjects | JE + Rabies + MenACWY-CRM197 | JE + Rabies |
|---|---|---|
| Injection site erythema | 0 | 1 |
| Hypersensitivity | 1 | 0 |
| Paresthesia | 0 | 1 |
| Erythema | 1 | 0 |
| Pruritus | 1 | 1 |
| Hot flush | 1 | 0 |
Collected over day 1 to day 29 (one month postvaccination); day 1 to day 57 (one month post last vaccination). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TF+YF | — | 0/101 (0%) | 27/101 (26.7%) |
| TF+YF+MenACWY-CRM197 | — | 0/100 (0%) | 30/100 (30%) |
| JE+Rabies | — | 1/99 (1%) | 23/99 (23.2%) |
| JE+Rabies+MenACWY-CRM197 | — | 1/101 (1%) | 22/101 (21.8%) |
| Rabies | — | 0/51 (0%) | 9/51 (17.6%) |
| MenACWY-CRM197 (Combined) | — | 0/100 (0%) | 9/100 (9%) |
| Event | TF+YF | TF+YF+MenACWY-CRM197 | JE+Rabies | JE+Rabies+MenACWY-CRM197 | Rabies | MenACWY-CRM197 (Combined) |
|---|---|---|---|---|---|---|
| InjuryInjury, poisoning and procedural complications | 0/101 | 0/100 | 1/99 | 0/101 | 0/51 | 0/100 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/101 | 0/100 | 0/99 | 1/101 | 0/51 | 0/100 |
| Event | TF+YF | TF+YF+MenACWY-CRM197 | JE+Rabies | JE+Rabies+MenACWY-CRM197 | Rabies | MenACWY-CRM197 (Combined) |
|---|---|---|---|---|---|---|
| Injection site painGeneral disorders | 12/101 | 8/100 | 6/99 | 4/101 | 2/51 | 2/100 |
| HeadacheGeneral disorders | 7/101 | 10/100 | 9/99 | 5/101 | 5/51 | 4/100 |
| Influenza like illnessGeneral disorders | 5/101 | 9/100 | 5/99 | 6/101 | 0/51 | 2/100 |
| NasopharyngitisInfections and infestations | 3/101 | 3/100 | 3/99 | 7/101 | 2/51 | 1/100 |
| Age, Continuous(years) | TF+YF | TF+YF+MenACWY-CRM197 | JE+Rabies | JE+Rabies+MenACWY-CRM197 | Rabies | MenACWY-CRM197 (Combined) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 36.5 ± 10.8 | 35.1 ± 11.0 | 35.0 ± 11.5 | 35.0 ± 11.1 | 35.8 ± 11.6 | 36.9 ± 11.2 | 35.7 ± 11.2 |
| Sex: Female, Male(Participants) | TF+YF | TF+YF+MenACWY-CRM197 | JE+Rabies | JE+Rabies+MenACWY-CRM197 | Rabies | MenACWY-CRM197 (Combined) | Total |
|---|---|---|---|---|---|---|---|
| Female | 49 | 44 | 53 | 50 | 21 | 50 | 267 |
| Male | 52 | 56 | 46 | 51 | 30 | 50 | 285 |
The record gives a start of Nov 2011, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 1 year 11 months after primary completion. A results delay was requested in Nov 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vi polysaccharide vaccine, typhoid · Yellow Fever Vaccine